Evidence map›Paper›PMID 41960765›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2026

Optimized reference region and the effect on test-retest reliability and sensitivity to differences between Parkinson's disease and control groups with [

Nikkita Khattar, David Matuskey, Jean-Dominique Gallezot, Mika Naganawa, Sophie E Holmes, Faranak Ebrahimian Sadabad, Mahsa Mayeli, Irina Esterlis, Christopher H van Dyck, Adam P Mecca and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Nikkita KhattarDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-3484-2452
David MatuskeyDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-7508-6572
Jean-Dominique GallezotDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.
Mika NaganawaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-4408-2621
Sophie E HolmesDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-4929-1932
Faranak Ebrahimian SadabadDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-6649-7211
Mahsa MayeliDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4656-156X
Irina EsterlisDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-6293-1458
Christopher H van DyckDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-1779-097X
Adam P MeccaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Deepak Cyril D'SouzaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-3141-1462
Nabeel B NabulsiDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-8129-0051
Sjoerd J FinnemaAbbVie Inc., North Chicago, IL, USA.ORCID 0000-0002-4972-3627
Yiyun HuangDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-6757-3220
Richard E CarsonDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-9338-7966
Takuya ToyonagaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-0369-8294

Funding

Medical Scientist Training ProgramT32GM136651 · NIGMS · YALE UNIVERSITY · PI BARBARA I KAZMIERCZAK · 2020 to 2026
$16.5M
PET Imaging of Synaptic Density in Alzheimers DiseaseR01AG052560 · NIA · YALE UNIVERSITY · PI CARSON, RICHARD E., VAN DYCK, CHRISTOPHER H · 2017 to 2020
$3.2M
SV2A PET Imaging in Healthy Subjects and Epilepsy PatientsR01NS094253 · NINDS · YALE UNIVERSITY · PI CARSON, RICHARD E. · 2016 to 2020
$2.8M
In vivo synaptic and dopamine transporter imaging in Parkinson's diseaseR01NS124819 · NINDS · YALE UNIVERSITY · PI DAVID A MATUSKEY · 2022 to 2026
$2.7M
NIA NIH HHS R01 AG052560NIGMS NIH HHS T32 GM136651NINDS NIH HHS R01 NS094253NINDS NIH HHS R01 NS124819
6 · The paper itself

Abstract

[

Indexed as

BrainParkinson DiseasePositron-Emission TomographyPyridinesRadiopharmaceuticalsAdultAgedCarbon RadioisotopesFemaleHumansMaleMiddle AgedPyrrolidinonesReproducibility of ResultsWhite Matter1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneCarbon RadioisotopesPyridinesPyrrolidinonesRadiopharmaceuticals[¹¹C]UCB-J PETParkinson’s diseasePET quantificationpositron emission tomographysynaptic density

Identifiers

PMID41960765
PMCPMC13068773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.